238 related articles for article (PubMed ID: 34935053)
1. Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways.
Huang XL; Liu C; Shi XM; Cheng YT; Zhou Q; Li JP; Liao J
Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34935053
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways.
Huang XL; Huang LY; Cheng YT; Li F; Zhou Q; Wu C; Shi QH; Guan ZZ; Liao J; Hong W
Int J Mol Med; 2019 Aug; 44(2):582-592. PubMed ID: 31173157
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of zoledronic acid derivatives with extended methylene linkers on osteoclastogenesis involve downregulation of JNK and Akt pathways.
Peng Y; Liu Q; Xu D; Li K; Li H; Qiu L; Lin J
Cell Biol Int; 2021 May; 45(5):1015-1029. PubMed ID: 33404170
[TBL] [Abstract][Full Text] [Related]
4.
Rattajak P; Aroonkesorn A; Smythe C; Wititsuwannakul R; Pitakpornpreecha T
Molecules; 2024 May; 29(9):. PubMed ID: 38731604
[TBL] [Abstract][Full Text] [Related]
5. Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression.
Lin W; Li XF; Ren DC; Song M; Duan L; Liu JZ; Zhan ZR
Mol Med; 2021 Feb; 27(1):19. PubMed ID: 33637048
[TBL] [Abstract][Full Text] [Related]
6. Amiloride inhibits osteoclastogenesis by suppressing nuclear factor-κB and mitogen-activated protein kinase activity in receptor activator of nuclear factor-κB-induced RAW264.7 cells.
Wang X; Zhu Y; Zheng S; Ni C; Zhao L; Liu C; Chen A; Xiao J
Mol Med Rep; 2015 May; 11(5):3451-6. PubMed ID: 25592168
[TBL] [Abstract][Full Text] [Related]
7. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
[TBL] [Abstract][Full Text] [Related]
8. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
9. Nicotinamide phosphoribosyltransferase inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation in vitro.
Baek JM; Ahn SJ; Cheon YH; Lee MS; Oh J; Kim JY
Mol Med Rep; 2017 Feb; 15(2):784-792. PubMed ID: 28035412
[TBL] [Abstract][Full Text] [Related]
10. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
11. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
12. The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages.
Henning P; Westerlund A; Movérare-Skrtic S; Lindholm C; Márquez-Méndez M; Nilsson S; Holmberg AR; Lerner UH
Invest New Drugs; 2024 Apr; 42(2):207-220. PubMed ID: 38427117
[TBL] [Abstract][Full Text] [Related]
13. Dihydroartemisinin attenuates osteoclast formation and bone resorption via inhibiting the NF‑κB, MAPK and NFATc1 signaling pathways and alleviates osteoarthritis.
Ding D; Yan J; Feng G; Zhou Y; Ma L; Jin Q
Int J Mol Med; 2022 Jan; 49(1):. PubMed ID: 34738623
[TBL] [Abstract][Full Text] [Related]
14. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
[TBL] [Abstract][Full Text] [Related]
15. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
16. Modulating calcium-mediated NFATc1 and mitogen-activated protein kinase deactivation underlies the inhibitory effects of kavain on osteoclastogenesis and bone resorption.
Guo Q; Cao Z; Wu B; Chen F; Tickner J; Wang Z; Qiu H; Wang C; Chen K; Tan R; Gao Q; Xu J
J Cell Physiol; 2018 Jan; 234(1):789-801. PubMed ID: 30078210
[TBL] [Abstract][Full Text] [Related]
17. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
18. C-phycocyanin attenuates RANKL-induced osteoclastogenesis and bone resorption in vitro through inhibiting ROS levels, NFATc1 and NF-κB activation.
AlQranei MS; Aljohani H; Majumdar S; Senbanjo LT; Chellaiah MA
Sci Rep; 2020 Feb; 10(1):2513. PubMed ID: 32054921
[TBL] [Abstract][Full Text] [Related]
19. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]